SCHEMBL22777315

SCHEMBL22777315

O=C(O)NCC1CCN(NC(=O)c2cc3cc(Cl)ccc3o2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATF4 P18848 9/20 0.56
L3MBTL1 Q9Y468 1/20 0.47
BCAT1 P54687 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
HRH4 Q9H3N8 1/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNA7 P36544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22777693 0.94 ATF4 (0.56) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL29447037 0.94 ATF4 (0.56) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL28722394 0.90 ATF4 (0.55) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL23920291 0.88 ATF4 (0.57) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL30578702 0.88 ATF4 (0.57) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL23920292 0.85 ATF4 (0.51) ATF4L3MBTL1NPC1RAB9AHRH4
SCHEMBL21819462 0.85 ATF4 (0.63) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL24998177 0.84 ATF4 (0.55) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL29988250 0.84 ATF4 (0.55) ATF4L3MBTL1BCAT1NPC1RAB9A
SCHEMBL21882069 0.84 ATF4 (0.57) ATF4L3MBTL1BCAT1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768877-A ISR inhibitor and preparation method and application thereof 中国药科大学 2023-09-19 CN disclosed
EP-3983378-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC (US) 2022-04-20 EP disclosed
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2021-10-14 US disclosed
WO-2020252205-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC (US) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 ATF4 1/4885L3MBTL1 1975/4885BCAT1 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.